National Institute on Drug Abuse (NIDA): Substance-Related Disorders trials

The registry lists 99 Substance-Related Disorders studies with National Institute on Drug Abuse (NIDA) as lead sponsor. 9 are open to participants now and 2 have results posted.

Phase 1 17Phase 2 26Phase 3 2Phase 4 12No phase 44(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Olfactory Function and Model-Based Behavior in People Living With HIV and SUDRecruitingNCT07637669
• Development of an Interview-Informed Timeline Follow-Back (TLFB) for Opioid Use in the Era of FentanylEnrolling by invitationNCT06995885
• Phase I Trial of High-Density Theta Burst Stimulation (hdTBS)Not yet recruitingNCT06868914Phase 1
• SMART-r: Substance Monitoring and Active Relapse Tracking RepositoryRecruitingNCT06676059
• Screening, Evaluation and Assessment (SEA) Protocol at the NIDA IRPRecruitingNCT06552741
• Orexin s Role in the Neurobiology of Substance Use DisorderRecruitingNCT05630781Not applicable
• Defining Neurobiological Links Between Substance Use and Mental IllnessRecruitingNCT05538910Not applicable
• Outcome Inference in the Sensory Preconditioning Task in Opioid-Use DisorderRecruitingNCT03745339
• Advanced Functional and Structural MRI Techniques for Neuropharmacological ImagingRecruitingNCT01036581Not applicable
• Biased Opioid Agonists for Treatment of Opioid Withdrawal in OUDTerminatedNCT04316559Phase 2Results posted
• Oxytocin and Cognitive Behavioral Therapy in Drug DependenceTerminatedNCT00975416Phase 4Results posted
• Real-world Momentary Assessment of Kratom Use Accompanied by Product Assays: A Natural-history Study for Interdisciplinary Characterization of Kratom Use and PharmacologyCompletedNCT05457803
• State and Trait Mediated Response to TMS in Substance Use DisorderWithdrawnNCT03707600Not applicable
• Impact of Delta Opioid Receptor Gene (OPRD1) Variations on Treatment Outcome in African AmericansCompletedNCT02225184
• Multi-Level HIV Prevention for Pregnant Drug AbusersCompletedNCT01976702Not applicable
• Understanding Drug Abuse Treatment OutcomesCompletedNCT01678833
• Individual Differences in Reward and Impulse ControlCompletedNCT01621607
• Evaluating Alternative Aftercare Models for Ex-offendersCompletedNCT01586689Phase 2
• Health Outcomes by Neighborhood - BaltimoreCompletedNCT01571752
• Effect of Varenicline on Tobacco Addiction and on Abstinence-induced Cognitive ImpairmentWithdrawnNCT01309685Phase 1
• Reinforcement-Based Treatment for Pregnant Drug AbusersCompletedNCT01177982Phase 2/3
• Characterization of Phenotypic and Genotypic Regressors for ImagingCompletedNCT01148381
• Neurobiology and Pharmacokinets of Acute MDMA AdministrationCompletedNCT01148342Phase 1
• Assessing Top Down and Bottom Up Attention Mechanisms in Smokers Using Nicotine Nasal SprayCompletedNCT01136642Phase 1
• Oral Fluid, Plasma and Whole Pharmacokinetics and Stability Following Smoked CannabisCompletedNCT01071616Phase 1
• Phase 1 Study to Evaluate RDC-0313 Coadministered With Buprenorphine to Opioid-Experienced Healthy AdultsCompletedNCT01046539Phase 1
• Optimizing Toxicological Screening in Drug Endangered ChildrenCompletedNCT01037569
• Effects of Nicotine on Brain Activity as Measured by fMRICompletedNCT01037153
• Influence of Nicotine on Cognitive Function in Schizophrenic Patients With and Without Comorbid Drug DependenceCompletedNCT01037075
• Effects of Nicotine on Cognitive Task Performance and Brain Activity as Measured by fMRICompletedNCT01036711
• Cognitive Task Development and Implementation for Functional MRI StudiesCompletedNCT01036685
• PET Assays of Striatal Dopamine Marker in Cocaine CravingCompletedNCT01036516
• The Effects of Expectation on Natural and Drug -Induced RewardsCompletedNCT01036230
• Screening Protocol for the Evaluation of Research ParticipantsCompletedNCT01036217
• Automatic Versus Evaluative Components of Cue ReactivityCompletedNCT01036126
• Reward Processing in Cocaine AddictionCompletedNCT01036074
• Effect of Functional Genetic Polymorphisms on Brain Morphology and FunctionCompletedNCT01035723
• Study of Smoking AbstinenceCompletedNCT01035632
• Effects of Nicotine on Elements of Attentions in Smokers and NonsmokersCompletedNCT01034020Phase 1
• Screening Protocol for the Evaluation of Research Participants at the Maryland Psychiatric Research Center (MPRC)CompletedNCT01030835
• Prenatal Drug Exposure: Effects on the Adolescent Brain and Behavior DevelopmentCompletedNCT01020669
• Brain Glutamate Receptors and Cocaine DependenceTerminatedNCT00951314
• Developing Field Tools for Real-Time Assessment of Exposure to Psychosocial Stress and Drug Use in an Outpatient Treatment PopulationCompletedNCT00787423
• Cognitive Behavioral Stress Management for HIV+ Drug AbusersCompletedNCT00722644Phase 1
• Reinforcement-Based Treatment and Abstinence-Contingent Housing for Drug AbusersCompletedNCT00685620Phase 4
• Integration of the Therapeutic Workplace in Drug CourtCompletedNCT00607360Phase 1
• Preventing Substance Use and Risky Behavior Among Rural African American YouthCompletedNCT00535704Not applicable
• Student Athlete Testing Using Random NotificationCompletedNCT00451854Not applicable
• Positive Choice: Prevention for Positive HealthCompletedNCT00447707Not applicable
• Randomized Trial of the Positive Action Program in Hawaii SchoolsCompletedNCT00328445Not applicable
• Effects of Fatty Acid Supplementation on Substance Dependent IndividualsCompletedNCT00312455Phase 2
• Step'n Out: A Multisite Trial of Collaborative Behavioral Management for Drug-Involved ParoleesStatus unknownNCT00302575Not applicable
• Contingency Management for Attendance - 2CompletedNCT00249639Not applicable
• Low-Cost Contingency Management for Hispanic Outpatients - 3CompletedNCT00249548Not applicable
• Vouchers vs. Prizes for Methadone Patients - 1CompletedNCT00249522Not applicable
• The Genetic Basis for Vulnerability to Substance AbuseCompletedNCT00247819
• Methylphenidate Studies for Drug Abuse Vulnerability Molecular GenenticsTerminatedNCT00247689
• Modifying Group Therapy for Bipolar Substance Abusers - 1CompletedNCT00227838Not applicable
• Effectiveness of Self-Help for Dually-Diagnosed Persons - 1CompletedNCT00218582Phase 1/2
• Treatment of Acute Hepatitis C Virus Infection With Pegylated Interferon in Injection Drug UsersCompletedNCT00194480Phase 4
• The Efficacy of Methadyl Acetate (LAAM) and Contingency Management Procedures for Treating Dual Opioid and Cocaine Abuse - 1CompletedNCT00158288Phase 2
• Rivastigmine For Methamphetamine Dependent IndividualsCompletedNCT00158210Phase 1
• Effectiveness of Bupropion in Treating Marijuana Dependent IndividualsCompletedNCT00142870Phase 2
• Addition of Naltrexone to Methadone TaperCompletedNCT00135759Phase 2
• Psychotherapy Enhancement for Therapeutic Community (TC) Retention - 1Status unknownNCT00086398Phase 2
• Substance Dependent Teens - Impact of Treating Depression Study 1 - 1CompletedNCT00061113Phase 4
• A Behavioral Trial for the Treatment of Methamphetamine Dependence. - 1Status unknownNCT00033124Phase 2
• A Study of Cabergoline for the Treatment of Cocaine Dependence - 1CompletedNCT00033111Phase 2
• Reserpine for the Treatment of Cocaine Dependence - 1CompletedNCT00033033Phase 2
• Buprenorphine/Naloxone in the Treatment of Heroin Dependence - 14CompletedNCT00015340Phase 4
• Methylphenidate Raclopride Positron Emission Tomography (PET) Test - 11CompletedNCT00015301Phase 4
• Pathophysiological Subtyping of Abnormalities in Cocaine Dependence - 9CompletedNCT00015275Phase 4
• Prepulse Inhibition of Startle in Cocaine Dependence - 7CompletedNCT00015249Phase 1
• Modeling Impaired Judgement in Cocaine Abusers - 6CompletedNCT00015236Phase 4
• Methylphenidate in the Treatment of Cocaine Dependent Patients With Adult Attention Deficit Hyperactivity Disorder - 5CompletedNCT00015223Phase 2
• Buprenorphine and Naloxone for the Treatment of Opiate Dependence - 1CompletedNCT00015171Phase 3
• Buprenorphine Dose Escalation Trial for Treatment of Non-Dependent Opiate Users - 2CompletedNCT00015041Phase 1
• Buprenorphine/Naloxone for Opiate-Dependence Treatment - 1CompletedNCT00015028Phase 2
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 7CompletedNCT00000358Phase 1
• Buprenorphine Maintenance for Opiate Dependence - 6CompletedNCT00000357Phase 2
• Evaluation of L-alpha-acetylmethadol (LAAM) in Methadone Patients - 5CompletedNCT00000356Phase 2
• Effects of Buprenorphine and Naloxone in Opiate Addicts - 4CompletedNCT00000355Phase 1
• Evaluation of Lofexidine for Treatment of Opioid Withdrawal - 3CompletedNCT00000354Phase 1
• Trial of Buprenorphine/Naloxone for Opiate Dependence - 2CompletedNCT00000353Phase 2
• Effects of Dextromethorphan on Opioid Tolerance in Methadone Patients - 1CompletedNCT00000352Phase 2
• Cognitive Correlates of Substance Abuse, Part 2 - 16Status unknownNCT00000351
• Cognitive Correlates of Substance Abuse - 11Status unknownNCT00000346Phase 4
• Brain Changes in Stimulant Dependent Subjects - 8CompletedNCT00000343Phase 4
• Methamphetamine Abuse Treatment in Patients With AIDS - 1CompletedNCT00000321Phase 4
• Buprenorphine Maintenance Dose Schedule and Treatment Setting - 1CompletedNCT00000318Phase 2
• Dextroamphetamine as an Adjunct in Cocaine Treatment - 1CompletedNCT00000304Phase 2
• Acute Withdrawal From Smoked Cocaine - 9CompletedNCT00000292Phase 1
• Flupenthixol and Haloperidol for Treating Cocaine Abuse Schizophrenics - 9CompletedNCT00000274Phase 2
• Pergolide Treatment for Substance Abusers - 4CompletedNCT00000269Phase 2
• Evaluation of a Desipramine Ceiling in Cocaine Abuse - 1CompletedNCT00000245Phase 2
• Flupenthixol Decanoate in Methamphetamine Smoking - 1CompletedNCT00000241Phase 2
• Pharmacotherapy and Intensive Treatment - 2CompletedNCT00000218Phase 4
• Treatment Efficacy for Drug Abuse and AIDS Prevention - 2CompletedNCT00000211Phase 2
• Treatment Efficacy for Drug Abuse and AIDS Prevention - 1CompletedNCT00000210Phase 2